Analysis of the effect of oral nutritional supplement or branched chain amino acid (BCAA) on liver cirrhotic patients with less than 3.5 g/dl of serum albumin level.

Analysis of the effect of oral nutritional supplement or branched chain amino acid (BCAA) on liver cirrhotic patients with less than 3.5 g/dl of serum albumin level. - Effect of oral nutritional supplement or BCAA on liver cirrhotic patients with less than 3.5 g/dl of serum albumin level.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011183

Enrollment

Registered

2013-07-13

Start date

2013-07-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Aminoleban EN powder mix LIVACT Granules

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cirrhotic patients with less than 3.5 g/dl of serum albumin level. 2.Cirrhotic patients diagnosed by physical, histological and/or ultrasound finding. 3.Patients who will be able to obtain written informed consent. 4.Patients who will be able to take drugs more than 3 months.

Exclusion criteria

Exclusion criteria: 1.Patients who are taking branched chain amino acid or oral nutritional supplement for liver failure. 2.Patients treated with albumin preparation. 3.Patients with refractory ascites. 4.Patients with history of hypersensitive against drugs. 5.Patients with liver cancer. 6.Patient with serious complications such as renal failure. 7.Patients who are heavy drinker more than 5 years. 8.Patient with refractory diabetes mellitus. 9.Patients who are pregnant or breastfeeding. 10.Patients whom cannot be obtained a written informed consent. 11.Patients judged to be inappropriate for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Serum albumin level Usefulness of nutritional supervision including LES	—

Countries

Japan

Contacts

Public ContactMikihiro Tsutsumi

Kanazawa Medical University Hepatology

076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026